Year Founded
2020
Ownership
Private
Employees
~10
Stage
Preclinical
Modalities
Small moleculeLarge molecule

IHP Therapeutics General Information

Developing IHP-102, a dual P-selectin and complement inhibitor for self-administered treatment of acute vaso-occlusive crisis in sickle cell disease

Contact Information

Website
Primary Industry
Biotech
Corporate Office
San Carlos, California
United States

Drug Pipeline

IHP-102
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to IHP Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

IHP Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view IHP Therapeutics's complete valuation and funding history, request access »

IHP Therapeutics Investors

UCLA Health TechQuity Accelerator
Investor Type: Venture Capital
Holding: Minority